- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
CDSCO flags 27 formulations as not of standard quality
Overview
In its latest drug safety alert, the apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) flagged 27 medicine batches for failing to qualify for a random drug sample test for the month of January.
These drug samples including Bochem Healthcare's Ferrous Sulphate & Folic Acid Tablets IP, Zee Laboratories' NITZO -2.6 (Controlled Release Tablets of Nitrogylcerin), Skymap Pharmaceuticals' WARZYME Digestive Enzymes (Pepsin & Fungal Diastase Syrup), Ortin Laboratories' Enalapril Maleate Tablets IP 5 mg, Om Biomedic's Pantoprazole Gastro- Resistant Tablets I.P., Terrace Pharmaceutical's Atenolol Tablets IP 50 mg and others are declared as 'Not of Standard Quality'.
For more information check out the full story on the link below:
Drug Alert: CDSCO Flags 27 Formulations As Not Of Standard Quality